| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S1473-3099(19)30612-7 |
| P698 | PubMed publication ID | 31879061 |
| P50 | author | Veerle Lejon | Q51760266 |
| François Chappuis | Q28817156 | ||
| P2093 | author name string | Elie A Akl | |
| Michael P Barrett | |||
| Gerardo Priotto | |||
| Jose Ramon Franco | |||
| Hanna Bergman | |||
| Gemma Villanueva | |||
| Andreas K Lindner | |||
| Pere Simarro | |||
| Olema Erphas | |||
| Jorge Seixas | |||
| Leon Kazumba | |||
| Erick Mwamba | |||
| Augustin Kadima Ebeja | |||
| P2860 | cites work | Clinical aspects of 2541 patients with second stage human African trypanosomiasis | Q38912264 |
| Human trypanosomiasis in the Ivory Coast: therapy and problems | Q40618909 | ||
| GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations | Q45412715 | ||
| Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children | Q46419741 | ||
| Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire. | Q46820909 | ||
| Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial | Q47637613 | ||
| Oral fexinidazole for human African trypanosomiasis | Q49896872 | ||
| How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. | Q51760220 | ||
| Where there is no brain imaging: Safety and diagnostic value of lumbar puncture in patients with neurological disorders in a rural hospital of Central Africa | Q56886534 | ||
| Monitoring the elimination of human African trypanosomiasis: Update to 2016 | Q60046224 | ||
| Improving the quality of WHO guidelines over the last decade: progress and challenges | Q88772538 | ||
| The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis | Q93075160 | ||
| How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs | Q26823483 | ||
| Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial | Q28250035 | ||
| A molecular mechanism for eflornithine resistance in African trypanosomes | Q28476349 | ||
| Should I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of Congo | Q28478935 | ||
| Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence | Q28538749 | ||
| Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial | Q28550204 | ||
| Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies | Q28550224 | ||
| GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables | Q29547885 | ||
| GRADE guidelines: 3. Rating the quality of evidence | Q29547891 | ||
| GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias) | Q29619791 | ||
| Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies | Q33681753 | ||
| Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). | Q34319076 | ||
| From health advice to taboo: community perspectives on the treatment of sleeping sickness in the Democratic Republic of Congo, a qualitative study | Q35345427 | ||
| Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness | Q35598430 | ||
| A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes | Q36516224 | ||
| Treatment options for second-stage gambiense human African trypanosomiasis | Q36551049 | ||
| Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo | Q37063849 | ||
| Intervention to promote patients' adherence to antimalarial medication: a systematic review. | Q37456044 | ||
| Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei | Q38270529 | ||
| Adherence to Artemisinin-Based Combination Therapy for the Treatment of Uncomplicated Malaria: A Systematic Review and Meta-Analysis | Q38544762 | ||
| P433 | issue | 2 | |
| P921 | main subject | African trypanosomiasis | Q203133 |
| P304 | page(s) | e38-e46 | |
| P577 | publication date | 2019-12-23 | |
| P1433 | published in | Lancet Infectious Diseases | Q15724248 |
| P1476 | title | New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice | |
| P478 | volume | 20 |
Search more.